Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Sweating and increased skin temperature caused by exercise can reduce physical activity and the willingness to exercise in adolescents with atopic dermatitis. This study was conducted to investigate the exercise load capacity of adolescents with atopic dermatitis and analyzed their exercise behavior and motivation. Adolescents with and without atopic dermatitis were assigned to the atopic dermatitis group and control group ( = 27 each). Both groups completed a cardiopulmonary exercise test and questionnaires to assess their exercise capacity, weekly exercise volume, exercise motivation, and self-efficacy, respectively. The ratio of measured forced vital capacity to the predicted forced vital capacity and the peak oxygen consumption of the atopic dermatitis group were significantly lower than those of the control group. The Godin Leisure-Time Exercise Questionnaire scores of the atopic dermatitis group were significantly lower than those of the control group. As for the Behavioral Regulation in Exercise Questionnaire 2, the scores for the introjected and identified regulations of the atopic dermatitis group were significantly lower than those of the control group. Regarding the Multidimensional Self-Efficacy for Exercise Scale, the scheduling efficacy and total scores of the atopic dermatitis group were significantly lower than those of the control group. Adolescents with atopic dermatitis had lower peak exercise capacity and lower weekly exercise volume. Furthermore, they lacked the negative feelings toward inactivity and the self-confidence to plan regular exercise independently. The results of this study suggest that adolescents with atopic dermatitis should be encouraged to engage in regular indoor exercise.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407882PMC
http://dx.doi.org/10.3390/ijerph191610285DOI Listing

Publication Analysis

Top Keywords

atopic dermatitis
44
adolescents atopic
24
dermatitis group
20
control group
20
exercise
17
group lower
16
lower control
16
exercise volume
12
dermatitis
11
atopic
10

Similar Publications

Human YKL-40 antibody alleviates atopic dermatitis-like skin inflammation by inhibiting exosome secretion via the JAK3/STAT6 pathway.

Arch Pharm Res

September 2025

College of Pharmacy and Medical Research Center, Chungbuk National University, 194-21, Osongsaengmyeong 1-ro, Osong-eup, Cheongju-si, Chungcheongbuk-do, 28160, Republic of Korea.

Atopic dermatitis (AD) is an inflammatory skin disease that produces a variety of inflammatory cytokines and chemokines. Chitinase-3-like protein 1 (CHI3L1, YKL-40) significantly contributes to AD-associated inflammatory response and is highly expressed in patients with AD. Therefore, this study elucidated the effects and potential mechanisms of human YKL-40 antibody on AD-affected skin.

View Article and Find Full Text PDF

Thunberg root extract inhibits atopic dermatitis-like skin symptoms.

Allergol Immunopathol (Madr)

September 2025

Inflamm-Aging Translational Research Center, Ajou University Medical Center, Suwon, Republic of Korea;

Thunberg is a perennial herbaceous plant of the genus that belongs to the Apiaceae family and is effective in improving inflammation, gout, and dizziness. However, the skin pruritus improvement effect and mechanism of action of Thunberg root extract (PJRE) have not yet been reported. We investigated the effects of PJRE on the regulation of pruritus and inflammatory responses in compound 48/80 (C48/80)-treated mice, phorbol 12-myristate 13-acetate (PMA)/A23187-induced human skin mast cells, and LPS-stimulated mouse macrophages.

View Article and Find Full Text PDF

Atopic dermatitis (AD) is a chronic inflammatory skin condition often complicated by cardiovascular comorbidities, impacting treatment options and outcomes. In this paper, we present a 41-year-old patient with severe AD, asthma, and chronic heart failure, who responded well to dupilumab, showing significant improvements in skin severity scores and heart function. This case underscores the effectiveness of dupilumab in managing AD alongside complex comorbidities.

View Article and Find Full Text PDF

Upadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review.

Clin Cosmet Investig Dermatol

September 2025

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People's Rep

Purpose: Alopecia areata (AA) is a common, immune-mediated, non-scarring form of hair loss. Janus kinase inhibitors provide considerable insight into the treatment of severe AA. However, the efficacy and safety of upadacitinib treatment of adolescents and pediatric patients with severe AA is unclear, especially in those without concomitant atopic diseases.

View Article and Find Full Text PDF